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Pharmacokinetics of oral and intravenous
melatonin in healthy volunteers
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Jacob Rosenberg1 and Ismail Gögenur4
Abstract
Background: The aim was to investigate the pharmacokinetics of oral and iv melatonin in healthy volunteers.
Methods: The study was performed as a cohort crossover study. The volunteers received either 10 mg oral
melatonin or 10 mg intravenous melatonin on two separate study days. Blood samples were collected at different
time points following oral administration and short iv infusion, respectively. Plasma melatonin concentrations were
determined by RIA technique. Pharmacokinetic analyses were performed by “the method of residuals” and
compartmental analysis. The pharmacokinetic variables: ka, t1/2 absorption, tmax, Cmax, t1/2 elimination, AUC0-∞, and
bioavailability were determined for oral melatonin. Cmax, t1/2 elimination, Vd, CL and AUC0-∞ were determined for
intravenous melatonin.
Results: Twelve male volunteers completed the study. Baseline melatonin plasma levels did not differ significantly
between the study days (P = 0.067). Mean (SD) t1/2 absorption of oral melatonin was 6.0 (3.1) min. Mean tmax was 40.8
(17.8) min with a median (IQR) Cmax of 3550.5 (2500.5–8057.5) pg ml
-1. Mean t1/2 elimination was 53.7 (7.0) min.
Median absolute bioavailability was 2.5 (1.7–4.7) %. Median Cmax after short iv infusion of melatonin was 389,875.0
(174,775.0–440,362.5) pg ml-1. Mean t1/2 elimination was 39.4 (3.6) min, mean Vd 1.2 (0.6) l kg
-1 and mean CL 0.0218
(0.0102) l min-1 kg-1.
Conclusions: This cohort crossover study estimated pharmacokinetics of oral and iv melatonin, respectively in
healthy volunteers. Bioavailability of oral melatonin was only 3 %.
Trial registration: Eudra-CT number: 2013-000205-23 (initial registration 27.03.2013).
Clinicaltrials.gov Identifier: NCT01923974 (initial registration 08.08.2013).
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Background
Exogenous melatonin is being increasingly employed as
treatment for various medical and surgical diseases [1, 2].
Furthermore, a recent study, administering intravenous
(iv) melatonin has documented reduced cardiac morbidity
and markers of myocardial ischemia following elective ab-
dominal aortic aneurism repair [3]. Despite its widespread
clinical use, the pharmacokinetic properties of exogenous
melatonin still need to be established further [4]. A limited
number of experimental studies in healthy volunteers have
performed direct comparisons of the pharmacokinetics of
oral and iv melatonin [5, 6]. The studies differed in number
of investigated subjects, dosages, methods and pharmacoki-
netic analyses [5, 6]. Accordingly, the pharmacokinetic
variables varied extensively between the studies [5, 6]. In
order to achieve an optimized clinical efficacy of mela-
tonin, further investigation of the pharmacokinetics is
clearly needed.
The aim of the study was to investigate the pharmaco-
kinetics of oral and iv melatonin in a cohort of healthy
volunteers.
Methods
Approvals were obtained from the Capital Region’s
Committee on Health Research Ethics (Protocol num-
ber: H-4-2013-013), the Danish Health and Medicines
* Correspondence: lphandersen@gmail.com
1Department of Surgery D, Herlev Hospital, University of Copenhagen, Herlev
DK-2730, Denmark
Full list of author information is available at the end of the article
© 2016 Andersen et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Andersen et al. BMC Pharmacology and Toxicology  (2016) 17:8 
DOI 10.1186/s40360-016-0052-2
Authority (Eudra-CT number: 2013-000205-23, Clinical-
trials.gov Identifier: NCT01923974) and the Danish Data
Protection Agency (Journal number: HEH-2013-008, nr:
02095) prior to inclusion of volunteers. Informed written-
and verbal consent were provided by all volunteers. The
blood samples relating to iv melatonin were obtained from
a primary trial investigating analgesic and anti-hyperalgesic
effects of melatonin (Eudra-CT number: 2013-000205-23,
Clinicaltrials.gov Identifier: NCT01923974). Data pre-
sented in the present paper have not been published
previously.
The study was performed as a cohort crossover study.
The volunteers received either 10 mg of oral melatonin
or 10 mg of iv melatonin on two separate study days.
Each study session was performed from 08:00 a.m. to
04:00 p.m. The study days were separated by 3 to
9 months. Inclusion criteria were age 20–40 years and
male gender. Volunteers were excluded, if they did not
understand written- or spoken Danish, suffered from
serious physical or mental illness, were diagnosed with a
sleep disorder, worked night shifts, received daily analge-
sics, had participated in other clinical trials within one
month from study inclusion or suffered from skin abnor-
malities on the lower extremities (due to the test para-
digm applied in the primary trial).
Oral melatonin consisted of one gelatine capsule con-
taining 10 mg melatonin. Volunteers were allowed 5 cl
of tap water to facilitate oral intake. Volunteers were
instructed to adhere to preoperative fasting guidelines
before the study session with oral melatonin (liquids:
minimum fasting period = 2 h; meals: minimum fasting
period = 6 h) [7]. Volunteers were encouraged to drink
and eat 2 h following oral melatonin administration.
Intravenous melatonin consisted of a 25 ml ethanol/sa-
line solution (2 ml 99.9 % ethanol/23 ml 0.9 % saline)
containing 10 mg of melatonin (Helsinn Chemicals SA,
Biasca, Switzerland). Intravenous melatonin was admin-
istered as short iv infusion in the left antecubital vein
(2.5 ml min-1; 10 min duration).
Blood samples were collected from a peripheral ven-
ous catheter inserted in the right antecubital vein at spe-
cified time points during each study session. The time
points differed between oral and iv melatonin. Oral
melatonin: at baseline (before medication = endogenous
melatonin production), and 0, 10, 20, 30, 40, 50, 60, 70,
80, 90, 100, 110, 120, 180, 240, 300, 360 and 420 min
after oral administration. Intravenous melatonin: at base-
line, and 0, 60, 120, 180, 240, 300, 360 and 420 min after
short iv infusion. Before each blood sample was col-
lected, a 3 ml volume of blood (residual volume) was
drawn from the peripheral venous catheter and dis-
carded. Fractionation of blood samples was performed at
5000 r.p.m. for 5 min, and plasma samples were stored
at -80 °C. Quantitative determination of plasma melatonin
concentrations was performed by radioimmunoassay
(RIA)-technique (Melatonin Direct RIA, DIAsource,
Louvaine-La-Neuve, Belgium). Precision of the RIA kit:
intra-assay coefficient of variation (CV) = 9.8–13.4 %,
inter-assay CV = 8.0–13.3 %. The limit of detection was
2.3 pg ml-1. Linearity of the kit ranged between 8.5–
529.0 pg ml-1. If plasma concentrations exceeded de-
tection range of the kit, plasma samples were diluted
according to manufacturer’s guidelines. All plasma sam-
ples were analysed in duplicate, and the mean value was
reported.
Statistical and pharmacokinetic analyses
Normality of data was assessed by visual inspection of re-
sidual plots and histograms. Parametric or non-parametric
tests were applied according to the distribution of data.
Correspondingly, data are presented as mean (SD) or
median (IQR), unless stated otherwise. A P-value < 0.05 is
considered statistically significant. Data were analysed
using IBM SPSS Statistics for Windows version 22.0 (IBM
Corp., Armonk, NY, USA) and Graph Pad Prism version
6.0 (Graph Pad Software Inc., La Jolla, CA, USA).
The baseline melatonin plasma concentrations of each
study day were compared using a paired sample T-test.
Baseline levels were not subtracted from post-treatment
(oral or iv) levels.
Pharmacokinetic analyses of oral and iv melatonin
were performed separately.
Oral melatonin
Time to maximal concentrations (tmax) and maximal
plasma concentrations (Cmax) were assessed directly at the
relevant time points. The pharmacokinetic variables: ab-
sorption constant (ka), absorption half-life (t1/2 absorption),
elimination rate constant (ke) and elimination half-life
(t1/2 elimination) were estimated by “the method of resid-
uals” [8]. Areas-under-the-curve (AUC) of plasma concen-
trations were calculated by applying the trapezoidal
rule [9]. AUC0-∞ was estimated as AUC0-420 min + (C420 min/
ke). Bioavailability was calculated as (AUC0-∞ oral /
AUC0-∞ IV) x 100.
Intravenous melatonin
Cmax was assessed directly at the time point, 0 min after
short iv infusion. Pharmacokinetic variables were calcu-
lated by compartmental analysis [10]. The pharmacoki-
netic variables: t1/2 elimination, volume of distribution (Vd)
and clearance (CL) were estimated from individual linear
regression lines of log-transformed (natural logarithm)
plasma concentrations. Following standard equations
were applied: t1/2 elimination = ln (2) / ke,Vd = dose / C0 min,
CL = ke x Vd. “Goodness of fit” of the individual linear re-
gression lines was assessed by the coefficient of determin-
ation, R2. AUC0-∞ IV was estimated, as described above.
Andersen et al. BMC Pharmacology and Toxicology  (2016) 17:8 Page 2 of 5
Results
Twelve male volunteers were included and completed the
study. Mean age and body mass index (BMI) were 27.1
(5.2) years and 23.2 (2.7) kg m-2, respectively. Baseline
melatonin plasma concentrations did not differ signifi-
cantly between the study days (before oral melatonin =
27.3 (13.5) pg ml-1; before intravenous melatonin = 18.3
(12.3) pg ml-1) (P = 0.067).
The pharmacokinetic variables of oral and iv mela-
tonin are presented in Tables 1 and 2.
Oral melatonin
Oral melatonin demonstrated first-order absorption and
elimination kinetics. Mean ka was 0.2 (0.1) min
-1, and
mean t1/2 absorption of oral melatonin was 6.0 (3.1) min
(Fig. 1). Mean tmax was 40.8 (17.8) min with a median
(IQR) Cmax of 3550.5 (2500.5–8057.5) pg ml
-1. Mean
t1/2 elimination was 53.7 (7.0) min, AUC0-∞ oral 281,538.3
(232,696.1–546,285.4) pg ml-1 min and median absolute
bioavailability was 2.5 (1.7–4.7) %.
Intravenous melatonin
The pharmacokinetic profiles of iv melatonin demon-
strated first-order elimination kinetics (Fig. 2). Median
Cmax after iv bolus injection of 10 mg melatonin was
389,875.0 (174,775.0–440,362.5) pg ml-1. Mean t1/2 elimination
was 39.4 (3.6) min, mean Vd 1.2 (0.6) l kg
-1 and mean CL
0.0218 (0.0102) l min-1 kg-1. Median R2 was 0.96 (0.93–
0.97). Median AUC0-∞ IV vas 14,179,767.6 (7,063,347.4–
18,964,804.0) pg ml-1 min.
Discussion
This cohort crossover study demonstrated a tmax of
41 min following oral administration. Cmax and AUC
varied extensively between volunteers in both administra-
tion routes. Elimination half-lives were 54 min and
39 min, respectively. Bioavailability of oral melatonin was
only 3 %, but demonstrated substantial inter-individual
differences.
Oral melatonin
Oral melatonin was absorbed by first-order kinetics,
which has previously been demonstrated in doses up to
80 mg [8]. The short t1/2 absorption of 6 min, corroborate
studies, applying similar oral drug formulations [8]. Ac-
cordingly, our tmax value of 41 min is in agreement with
other studies, documenting values ranging from 30 to
60 min [6, 11]. Oral administration of exogenous mela-
tonin, approximately 45 min before intended onset of
clinical effects therefore seems reasonable, assuming that
clinical efficacy coincides with tmax values [12]. Oral ad-
ministration was associated with extremely variable Cmax
and AUC0-∞ oral values, which has been described previ-
ously [5]. The inter-individual variations are apparently
caused by differences in absorption, distribution, metab-
olism or excretion of the drug, but the exact causes and
clinical implications remain unestablished so far [5]. Pre-
vious studies demonstrate t1/2 elimination values ranging
from 46 to 65 min in oral doses from 0.5 to 6 mg [5, 6, 11],
which correlates with our findings of 54 min. Our data
demonstrated a very low absolute bioavailability of 3 %, al-
beit with a substantial inter-individual variability. Previous
experimental studies have documented higher values ran-
ging between 9 and 33 %, although with comparable inter-
individual variability [5, 6, 12]. It is well established in both
animal- and human studies that the low bioavailability re-
sults from an extensive hepatic first pass metabolism [5].
Similarly, it is also clear that these findings may mandate
future dose regulations between different administration
routes. However, a general lack of experimental- and clin-
ical studies correlating melatonin plasma concentration
levels and clinical effects still remains, and further know-
ledge is needed, preferably by in-depth pharmacokinetic-
pharmacodynamic modelling.
Intravenous melatonin
Previous studies investigating iv administration of mela-
tonin have also demonstrated first-order eliminations
kinetics [10], as observed in our study. As with oral
melatonin, iv administrations displayed extensive varia-
tions in Cmax and AUC0-∞ IV values, which is in accord-
ance with previous studies [6]. Other studies also
documented t1/2 elimination values ranging between 28 and
60 min in iv doses from 0.005 mg to 2 mg [6, 10, 13],
which corresponds to the 39 min, demonstrated in the
present study. Several studies confirm that elimination
rates of iv melatonin (and oral melatonin) are not related
to the administered dose. Similarly, previous studies docu-
ment CL values of 0.013 l min-1 kg-1 (weight-corrected)
[13] and 0.027 l min-1 kg-1 [10], which correspond well
to our findings of 0.022 l min-1 kg-1. Cavallo and col-
leagues also documented a VD of 1.8 l kg
-1 [10], which
is comparable with a value of 1.2 l kg-1, demonstrated
in our study.
Table 1 Pharmacokinetic variables of 10 mg of oral melatonin
t1/2 absorption min tmax min Cmax pg mL
-1 t1/2 elimination min AUC0-∞ oral pg ml
-1 min f %
6.0 (3.1) 40.8 (17.8) 3550.5 (2500.5–8057.5) 53.7 (7.0) 281,538.3 (232,696.1–546,285.4) 2.5 (1.7–4.7)
Absorption half-life, time to maximal concentration and elimination half-life data are presented as mean (SD). Maximal concentration, area-under-the-curve and
bioavailability data are presented as median (IQR)
Absorption half-life, t1/2 absorption; time to maximal concentration, tmax; maximal plasma concentration, Cmax; elimination half-life, t1/2 elimination; area-under-the-curve,
AUC; bioavailability, f
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Strengths
Our study is the first to perform direct comparisons of
pharmacokinetics of oral and iv melatonin in doses rou-
tinely administered perioperatively (approximately 10 mg)
[2]. The study was performed as a crossover study to re-
duce the effect of the inter-individual variability on phar-
macokinetic data. Our experimental setup included
multiple blood samples for a detailed description of both
absorption and elimination phases in both administration
routes. Our study also included standard pharmacokinetic
methods, such as “the method of residuals” and compart-
mental analysis [8, 10]. In addition, we chose to include
the coefficient of determination (R2) to document the
“goodness of fit” of the individual linear regression lines in
the compartmental analysis. Our data demonstrated a R2
value of 0.96, indicating a high degree of “fit” of the first-
order pharmacokinetic model, and, hence, a considerable
accuracy of the derived pharmacokinetic variables.
Limitations
First, this study only included healthy male volunteers in
an experimental setup. Hence, a potential gender differ-
ence in pharmacokinetic variables may exist. Further-
more, previous experimental studies indicate that the
pharmacokinetics of melatonin is affected by age [10] and
external factors, such as caffeine intake [14] cigarette
smoking [15] and the use of oral contraceptives [16]. Also,
a low number of clinical studies have demonstrated al-
tered pharmacokinetic variables of melatonin [17–19] in
e.g. critically ill patients [17, 18]. Interestingly, most other
patient groups, e.g. surgical patients, still remain to be
investigated. Comorbidity and drug interactions may
change the pharmacokinetics of melatonin, potentially al-
tering clinical efficacy of the drug [20].
Second, oral and iv study sessions were separated by 3
to 9 months for each volunteer. These time periods may
theoretically have affected the comparability of individ-
ual pharmacokinetic variables, despite the crossover de-
sign. It, however, seems unlikely, as all volunteers were
healthy young males in stable physical conditions.
Third, the very low bioavailability of oral melatonin
documented in our study may indicate a deficient ab-
sorption of the drug in our setup. The volunteers were
allowed 5 cl of tap water to facilitate intake of oral mela-
tonin. Hence, it can be discussed, if the restricted liquid
volume, despite saliva and gastric/intestinal fluid secre-
tions was sufficient to dissolve and present the ingested
melatonin to the small intestine, where absorption is
mainly achieved. We, however, chose this amount of
water to standardize the experimental conditions and to
imitate a clinical premedication scenario [2, 7]. Also, we
administered an easily absorbable gelatine capsule in
order to optimize dissolution of the drug. Finally, com-
parable tmax values between the volunteers were demon-
strated, suggesting that an impeded absorption is rather
unlikely.
Conclusions
This crossover cohort study investigated the pharmaco-
kinetics of oral and intravenous melatonin in healthy
male volunteers. Oral melatonin was rapidly absorbed,
and Tmax was achieved after 41 min. Cmax and AUC
Table 2 Pharmacokinetic variables of 10 mg of iv melatonin
Cmax pg ml
-1 t1/2 elimination min Vd l kg
-1 CL l min-1 kg-1 R2 AUC0-∞ IV pg ml
-1 min
389,875.0 (174,775.0–440,362.5) 39.4 (3.6) 1.2 (0.6) 0.0218 (0.0102) 0.96 (0.93–0.97) 14,179,767.6 (7,063,347.4–18,964,804.0)
Maximal concentration, coefficient of determination and area-under-the-curve data are presented as median (IQR). Elimination half-life, volume of distribution and
clearance data are presented as mean (SD)
Maximal plasma concentration, Cmax; elimination half-life, t1/2 elimination; volume of distribution, Vd; clearance, CL; coefficient of determination, R
2;
area-under-the-curve, AUC
Fig. 1 Pharmacokinetic profile of 10 mg of oral melatonin. The dots
represent mean values. Whiskers represent SEM Fig. 2 Individual pharmacokinetic profiles of 10 mg of iv melatonin
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varied extensively between volunteers. Elimination half-
lives following oral and intravenous melatonin admin-
istration was 54 min and 39 min, respectively. The
bioavailability of oral melatonin was only 3 %, but a
considerable variability between the volunteers was
noted.
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